United Capital Financial Advisers LLC Increases Position in Zoetis Inc (ZTS)

United Capital Financial Advisers LLC increased its holdings in Zoetis Inc (NYSE:ZTS) by 57.1% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 18,452 shares of the company’s stock after purchasing an additional 6,710 shares during the period. United Capital Financial Advisers LLC’s holdings in Zoetis were worth $1,541,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Robecosam AG increased its position in Zoetis by 4.6% in the fourth quarter. Robecosam AG now owns 15,346 shares of the company’s stock worth $1,111,000 after purchasing an additional 679 shares during the last quarter. Wealthfront Inc. increased its position in Zoetis by 4.4% in the first quarter. Wealthfront Inc. now owns 16,352 shares of the company’s stock worth $1,366,000 after purchasing an additional 688 shares during the last quarter. Dynamic Advisor Solutions LLC increased its position in Zoetis by 5.0% in the first quarter. Dynamic Advisor Solutions LLC now owns 14,968 shares of the company’s stock worth $1,250,000 after purchasing an additional 718 shares during the last quarter. Advisory Services Network LLC increased its position in Zoetis by 42.4% in the fourth quarter. Advisory Services Network LLC now owns 2,423 shares of the company’s stock worth $175,000 after purchasing an additional 721 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its position in Zoetis by 16.0% in the first quarter. Jones Financial Companies Lllp now owns 5,337 shares of the company’s stock worth $446,000 after purchasing an additional 738 shares during the last quarter. Institutional investors own 90.09% of the company’s stock.

Zoetis opened at $85.82 on Friday, Marketbeat.com reports. The company has a current ratio of 4.27, a quick ratio of 2.83 and a debt-to-equity ratio of 2.51. Zoetis Inc has a twelve month low of $59.50 and a twelve month high of $89.25. The firm has a market cap of $42.11 billion, a price-to-earnings ratio of 35.76, a PEG ratio of 1.92 and a beta of 0.98.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Wednesday, May 2nd. The company reported $0.75 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.69 by $0.06. The business had revenue of $1.37 billion for the quarter, compared to analysts’ expectations of $1.35 billion. Zoetis had a net margin of 17.97% and a return on equity of 68.51%. The business’s revenue was up 11.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.53 earnings per share. analysts anticipate that Zoetis Inc will post 3.06 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 4th. Stockholders of record on Friday, July 20th will be issued a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.59%. The ex-dividend date of this dividend is Thursday, July 19th. Zoetis’s payout ratio is presently 20.83%.

Several brokerages recently weighed in on ZTS. Cantor Fitzgerald restated a “buy” rating and issued a $98.00 price target on shares of Zoetis in a research report on Wednesday, May 16th. BMO Capital Markets restated a “hold” rating and issued a $80.00 price target on shares of Zoetis in a research report on Wednesday, May 16th. Craig Hallum restated a “buy” rating and issued a $94.00 price target (up previously from $87.00) on shares of Zoetis in a research report on Wednesday, April 25th. ValuEngine upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Finally, Jefferies Financial Group set a $97.00 price target on shares of Zoetis and gave the stock a “buy” rating in a research report on Monday, February 26th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company’s stock. Zoetis presently has an average rating of “Buy” and a consensus target price of $84.73.

In other news, insider Kristin C. Peck sold 4,877 shares of the company’s stock in a transaction dated Tuesday, May 1st. The shares were sold at an average price of $83.46, for a total value of $407,034.42. Following the transaction, the insider now directly owns 42,652 shares in the company, valued at $3,559,735.92. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.35% of the company’s stock.

Zoetis Profile

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply